company that he transformed from a technology provider into a leading drug
discovery and development company with a promising pipeline targeting the
central nervous system. He accomplished this through a strategic approach and
by achieving the corporate and financial milestones required, including a
number of acquisitions and funding rounds. Mr. Aldag started at Evotec as CFO
in 1997. Since 2007, Mr. Aldag has also been Chairman of the Board of
Molecular Partners in Switzerland. Before joining the life sciences industry
Mr. Aldag held senior management positions at MAN, the German Privatization
Agency Treuhandanstalt, and at Daimler Benz. From 2002 to 2008 Mr. Aldag also
served as a Member of the German Monopoly Commission.
Mr. Aldag holds business degrees from the European Business School and
from the Harvard Business School.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to circumvent
many if not all of the obstacles that have prevented gene therapy from
becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV)
vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate what is probably the first stable and
scalable AAV production platform. As such, AMT's proprietary platform holds
tremendous promise for thousands of rare (orphan) diseases, especially those
that are caused by one faulty gene. Currently, AMT has a product pipeline
with nine products at different stages of development.
Certain statements in this press release are "forward-looking statements"
including those that refer to management's plans and expectations for future
operations, prospects and financial condition. Words such as "strategy,"
"expects," "plans," "anticipates," "believes," "will," "continues,"
"estimates," "intends," "projects," "goals," "targets" and othe
Page: 1 2 3 Related medicine news :1
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2009 PR Newswire.
All rights reserved
. Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer2
. The Childrens Center of Wayne County Appoints Ballantyne as Chief Development Officer3
. GENova appoints Dr. Wang Chong to Scientific Advisory Board4
. InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer5
. Delcath Systems, Inc. Appoints David McDonald Chief Financial Officer6
. GENova appoints Dr. Philip Gould to Scientific Advisory Board7
. GENova appoints Director of Asian business development8
. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board9
. Allscripts to Announce Fiscal First Quarter Results on September 29, 2009; Company Appoints Vice President of Investor Relations10
. KV Pharmaceutical Appoints Interim Chief Financial Officer11
. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer